Small Pharma (CVE:DMT) shares down 6.3%

Small Pharma (CVE:DMT) shares down 6.3%


Shares of Small Pharma Inc. (CVE:DMT – Get Free Report) were down 6.3% during Monday trading. The stock traded as low as C$0.15 and was last traded at C$0.15. About 1,890,765 shares were traded at midday trading, an increase of 538% compared to its average daily volume of 296,159 shares. The stock previously closed at C$0.16.

Small Pharma Stocks Drop 6.3%

The company has a debt-to-equity ratio of 5.95, a quick ratio of 6.28 and a current ratio of 2.63. The company has a market cap of C$50.37 million, a PE ratio of -2.14 and a beta of 0.86. The company has a fifty-day moving average price of C$0.15 and a 200-day moving average price of C$0.15.

Profile of a small pharmaceutical company

(Get free report)

Small Pharma Inc, a biotechnology company, focuses on the development of short-term psychedelic therapies for the treatment of mental disorders. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company’s product line includes SPL026, which is in Phase IIa clinical trials for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trials, as well as SPL801B, an oral dosage form.

Featured Stories



Get news and reviews for Small Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings on Small Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.